Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novella Names Reg Affairs Head | Contract Pharma
Breaking News, Promotions & Moves

Novella Names Reg Affairs Head

Johnson to support oncology, biopharma, device clients

Kevin B. Johnson, Ph.D., has been named global head regulatory affairs at Novella Clinical. Dr. Johnson will support Novella’s global oncology, biopharma and medical device clients. He is experienced in regulatory authority interactions and strategic regulatory liaison activities for drugs, biologics, cell and tissue-based products, combination products, and medical devices and has worked in international clinical development teams across a number of therapeutic areas. He has lead a variety of regulatory authority meetings and managed regulatory submissions including INDs, IDEs, NDAs/BLAs, 510(k)s, and PMAs.

Dr. Johnson has nearly 20 years of clinical research experience, serving both sponsors and CROs in regulatory capacities. He most recently worked as director of Regulatory Affairs and Quality Systems for the Wake Forest Institute for Regenerative Medicine. Previous experience includes senior regulatory and clinical positions with PPD, Parion Sciences, PharmaKnowledge and Health Decisions.

Novella Clinical chief operating officer Rob King noted, “Kevin’s depth of regulatory experience, key relationships with agency officials and knowledge across both biopharma and device sponsors will serve Novella and our clients very well.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters